ESSA Pharma Q3 2025 Earnings Report

ESSA Pharma EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.24
• Beat/Miss: N/A
• One Year Ago EPS: N/A

ESSA Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ESSA Pharma Announcement Details

• Quarter: Q3 2025
• Date: 8/4/2025
• Time: Before Market Opens
• Conference Call Date: Monday, August 4, 2025
• Conference Call Time: 7:00AM ET

ESSA Pharma (NASDAQ:EPIX) is a clinical‐stage pharmaceutical company dedicated to developing novel therapies for prostate cancer. The company’s proprietary approach targets the androgen receptor (AR) via its N-terminal domain, a strategy designed to overcome resistance mechanisms that limit current hormone therapies. ESSA’s lead candidate leverages this unique mechanism to address castration‐resistant prostate cancer, positioning the company at the forefront of AR-focused drug discovery.

Central to ESSA’s pipeline is its second‐generation AR N-terminal domain inhibitor, which builds on the proof-of-concept established by the company’s first‐generation program. This investigational therapy is engineered to bind a site on the AR that is not addressed by existing treatments, offering potential benefits for patients who have progressed on standard therapies. Ongoing clinical studies are evaluating safety, tolerability and initial efficacy signals in men with advanced prostate cancer.

Founded in 2014 and headquartered in Vancouver, Canada, ESSA Pharma also maintains research facilities in the United States to support its global clinical development efforts. The company collaborates with academic institutions and clinical partners across North America and Europe, enrolling patients at leading cancer centers. These partnerships enable ESSA to accelerate trial timelines and broaden access to its investigational agents.

ESSA Pharma is led by President and Chief Executive Officer Kelly Martin, Ph.D., whose background spans oncology drug development and strategic biopharmaceutical leadership. The executive team includes seasoned professionals in clinical operations, regulatory affairs and commercial planning, supported by a scientific advisory board composed of experts in prostate cancer biology and translational research.